Brandon Capital

Are you, or do you know a Radiochemist? Advancell is hiring! They recently raised over USD 112 million, signed a partnership with Eli Likly and have an incredible leadership team so it’s worth a look and/or a share.

Thanks to Amy Brown from BiotechTV for chatting with Aravax CEO Pascal Hickey about the company's future and CSO Sara Prickett about the potential advantages of treating peanut allergies with a peptide-based approach. 🔬 Aravax’s innovative peptide-based approach “What sets our approach apart is the ability to avoid treatment-induced acute reactions, which are a significant limitation of current therapies.” 🏭 Expanding late-stage manufacturing “Scaling up our manufacturing capabilities is critical as we prepare for Phase 3 trials. It’s about ensuring we have the capacity to deliver the commercial product to the final stage of clinical development when the Phase 2 trial completes in 2026.” 🌍 Beyond peanuts “We’re not just stopping at peanuts—our platform has the potential to transform how a wide range of food allergies are treated.” 📊 What’s next? "Phase 2 trial data will be shared mid-next year. Aravax is using this time to prepare for Phase 3, ensuring no lag in bringing this groundbreaking therapy to people living with and impacted by peanut allergies." Full interview in the comments 👇 #Biotech #Innovation #AllergyTreatment #Aravax #BrandonCapital #LifeSciences #PeptideTherapy #Healthcare

🌟 Meet our UK Partner, Jonathan Tobin, in Singapore Don't miss hearing our UK Partner, Jonathan Tobin, and Head of JLABS Singapore, Alessandro Falcone, MD, explore the critical role of venture capital in advancing life sciences innovation this week. 📅 Friday, 28 February ⏰ 3:30 PM - 6:30 PM SGT 📍 HUONE, 3D River Valley Road, 03-01 Clarke Quay, Singapore 👉 Register your interest here: https://lnkd.in/gjtD6PN7 And we'd appreciate you tagging people in Singapore interested in learning more about Brandon Capital and Life Sciences Venture Capital.  #VentureCapital #LifeSciences #Innovation #Healthcare #Biotech #Investment #Singapore

📣 Thanks to Bronwen Clune and Capital Brief for covering AdvanCell's recent raise. With growing global interest in #radiopharmaceuticals, this milestone reinforces Australian biotech's role in delivering transformative global health solutions. "The model is to manufacture the generator which encompasses that 1.9-year half-life, manufacture that in Brisbane, and then send those generators from Brisbane to the US," CEO Andrew Adamovich This allows AdvanCell to maintain its Australian manufacturing base while establishing production sites closer to patients in major markets. And we'll leave the final word on what this achievement represents for Australian biotech to AdvanCell and Brandon BioCatalyst Chair Bill Ferris: "Investors are now realising that there's money to be made and good things to be created in biotech. This sector presents a global opportunity – almost an obligation – for Australia to step up. We're going to see a fantastic couple of decades ahead for both the sector and Australia." We couldn't agree more! Full article 👇🏾 https://lnkd.in/gYbj6dgn

Congratulations to Axelia Oncology who has entered a clinical supply agreement with Regeneron, that relates to Axelia's Phase 1 clinical trial. 🔬Agreement will explore the combination of Axelia’s candidate AXA-042, an innate immune modulator targeting toll-like-receptors (TLR) 2/6 and Regeneron’s PD-1 inhibitor Libtayo® (cemiplimab). 🔬Evaluate the safety and tolerability of AXA-042, both as a monotherapy and in combination with Libtayo across a range of solid tumour. 🔬Clinical study will be initiated at six clinical trial sites in Australia. "We are excited to have the opportunity to assess AXA-042 in combination with Libtayo. Regeneron’s continued investment in immuno-oncology innovation is clearly aligned with our approach to cancer immunotherapy and we are delighted to be working with them as we progress through the clinic” Phil Kearney, Axelia Oncology. Congratulations to the Axelia team on a partnership that marks a promising step in advancing innovative cancer therapies. #Biotech #CancerResearch #ImmunoOncology

🌟 Congratulations to ENA Respiratory, who announced they've received a US$5 million investment from Flu Lab, to advance their INNA-051, their virus-agnostic candidate designed to minimise the impact of respiratory infections. 🤧INNA-051 primes the body’s innate immune response, the natural first line of defence. 🤧 Delivered as a convenient once-weekly nasal dry powder, it's designed to protect at-risk groups, including the elderly, essential workers, and individuals with chronic conditions. Flu Lab’s funding will support a Phase II community infection study in the US. The study will assess INNA-051’s safety and efficacy in reducing symptomatic respiratory infections, including those caused by influenza, coronaviruses, and more. “There is an urgent need for new approaches to reduce the burden of serious viral respiratory infections. This investment from Flu Lab accelerates our clinical program and is a strong endorsement of INNA-051’s potential to make a meaningful difference in reducing mortality and morbidity.” Christophe Demaison 👏👏🏽👏🏿 to the ENA Respiratory team and full press release 👇🏼 https://lnkd.in/e2_m4cvm #Biotech #HealthInnovation #RespiratoryHealth #InnateImmunity #LifeSciences

🚀Congratulations to Brandon Capital portfolio company AdvanCell on expanding the scope and breadth of its collaboration with Eli Lilly and Company. Advancell CEO, Andrew Adamovich “By combining our groundbreaking isotope production capabilities, our team’s expertise and infrastructure with Lilly’s pharmaceutical and oncology expertise and global scale, we aim to bring transformative treatments to patients with hard-totreat cancers. It is especially pleasing to continue and expand our existing relationship.” Well done to the exceptional team on what has been a very big week! #LifeSciences #CancerInnovation #TargetedAlphaTherapies

🚀Wonderful to see CUREator awardee Exosome BioSciences begin clinical trials for their innovative potential therapy for people living with #CrohnsDisease, thanks to funding from the Medical Research Future Fund.

🌟 AdvanCell Secures US$112 Million Series C Financing! Brandon Capital is excited to join Queensland-based AdvanCell’s journey as a new investor in their oversubscribed US$112 million Series C funding round. The Series C was co-led by SV Health Investors, Sanofi Ventures, Abingworth and SymBiosis. With additional support coming from existing investor Morningside Technology Advisory LLC, we joined fellow local investor Tenmile as new investors. Radiopharmaceuticals represent an innovative and up-and-coming area of oncology, so it's wonderful to see syndicate of local and international investors coming together to support AdvanCell’s mission of transforming cancer care. AdvanCell’s innovative approach to harnessing Pb-212-based therapies positions them as a leader in this potentially transformative field. ✅40,000-square-foot manufacturing facility to scale production ✅First-in-class Pb-212 Targeted Alpha Therapy in clinical trials for metastatic prostate cancer ✅ Robust pipeline of radionuclide therapies addressing unmet needs Congratulations to Andrew Adamovich and the Advancell team. Read more about AdvanCell's plans via the articles linked in the comments.👇 #Radiopharmaceuticals #TargetedAlphaTherapy #BiotechInnovation #CancerCare #BrandonCapital

📢 Biotech Seminar for South Australian researchers with Dr Roberto Solari "Myricx Bio: A Case History of a University Spinout” Myricx Bio originates from research generated by the Imperial College London and the Francis Crick Institute and has subsequently secured one of the largest Series A financings for a UK university spinout. Co-founder and founding CEO of Myricx Bio, Dr Solari has decades of experience in drug discovery and company building, including pivotal roles at GSK, Astex Pharmaceuticals, and Heptares. In the seminar Dr Solari will share his founder experience, providing unique insights into the challenges and triumphs of building a company at the intersection of science and business. 📅 Monday, 24 February 🕒 10:00–11:30 AM (Presentation + Networking over morning tea) 📍 SAHMRI Auditorium, North Terrace, Adelaide Registration 🔗 Register by Friday 14 February to secure your place https://lnkd.in/g9mVm36s Thanks to our partners for their support Government of South Australia Health, University of Adelaide, University of South Australia, Flinders University and SAHMRI. cc Melissa McBurnie #BiotechInnovation #UniversitySpinouts #LifeSciences #SouthAustralia